RSS feeds allow Web site content to be gathered via feed reader software. Click the subscribe link to obtain the feed URL for this page. The feed will update when new content appears on this page.

Gilead Sciences Inc.

A collection of news and information related to Gilead Sciences Inc. published by this site and its partners.

Top Gilead Sciences Inc. Articles

Displaying items 1-11
  • Michelle Quinn: Getting more workforce data out of Silicon Valley firms

    Last month, as I mentioned in a previous column, the San Jose Mercury News sent a letter to major Silicon Valley firms asking for information about their companies' work force demographics. And in that previous column, I said I'd update you on how...
  • InterMune drug may offer big upside to Roche if aimed at liver

    (Reuters) - Roche Holding AG's planned $8 billion purchase of InterMune Inc is centered around hopes for blockbuster sales of its lung drug, but the smaller company's development pipeline may end up giving the Swiss drugmaker a far bigger bang for its...
  • 'Plantibodies' drugs advance as big pharma stands aside

    LOS ANGELES (Reuters) - Biotech drug production techniques based on plants, which may prove to be faster, higher yielding and cheaper than current methods using mammalian cells, haven't caught on with the biggest pharmaceutical companies. The leading...
  • Achillion's hepatitis C drug shows promise in trial

    (Reuters) - Achillion Pharmaceuticals Inc said all patients treated with its experimental hepatitis C drug showed no detectable levels of the virus four weeks after the therapy, sending its shares up 18 percent. The mid-stage trial tested Achillion's...
  • Gilead says panel rejects Roche's claims on hepatitis C drug

    (Reuters) - Gilead Sciences Inc said an arbitration panel rejected Roche Holding AG's patent infringement claims related to Gilead's hepatitis C drug, Sovaldi. Gilead's shares rose as much as 3 percent in early trading. "While this outcome was widely...
  • New health apps, games reward patients who take their meds

    SAN FRANCISCO (Reuters) - A group of ex-gaming industry executives say they can use their design chops to solve a major health challenge: Sick patients neglecting to take their medication and costing employers and insurance providers billions of dollars....
  • UK cost body backs pricey Gilead hepatitis pill for some patients

    LONDON (Reuters) - Gilead Sciences' expensive new hepatitis C pill has been endorsed for use in certain patients by Britain's healthcare cost-effectiveness watchdog, after the U.S. firm provided more information. The National Institute for Health and...
  • Healthcare: A remedy for long-term investors

    CHICAGO (Reuters) - (The opinions expressed here are those of the author, a columnist for Reuters.) For healthcare, gray is the new black. The fastest-growing segment of the global population is aged 60 and over, according to the United Nations...
  • Patients pay steep price for Hepatitis C cure

    Patients pay steep price for Hepatitis C cure
    There's a new breakthrough hepatitis C drug treatment that cures — yes, cures — almost everyone who takes it. Unlike previous, far less effective treatments, patients suffer few if any side effects. The entire regimen takes only 12 weeks, much...
  • U.S. senators ask Gilead Sciences to explain high cost of hepatitis C drug

    Two U.S. senators asked Gilead Sciences Inc. to produce documents explaining why its new hepatitis C drug is priced at $84,000 per treatment course, raising renewed concerns over the high costs to taxpayers. In a letter sent Friday, Ron Wyden (D-Ore.)...
  • Gilead Sciences' $84,000 price for hepatitis drug is scrutinized

    U.S. lawmakers have asked Gilead Sciences Inc. to justify the price of its new $84,000 drug for hepatitis C patients amid growing concern about the high cost to taxpayers and consumers. In a letter to the Foster City, Calif., company, Rep. Henry A....